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Abstract
Background: Pompe disease is a rare lysosomal storage disorder characterized by muscle weakness and wasting.
The majority of adult patients have slowly progressive disease, which gradually impairs mobility and respiratory
function and may lead to wheelchair and ventilator dependency. It is as yet unknown to what extent the disease
reduces the life span of these patients. Our objective was to determine the survival of adults with Pompe disease
not receiving ERT and to identify prognostic factors associated with survival.
Methods: Data of 268 patients were collected in a prospective international observational study conducted
between 2002 and 2009. Survival analyses from time of diagnosis and from time of study entry were performed
using Kaplan-Meier curves and Cox-proportional-hazards regression.
Results: Median age at study entry was 48 years (range 19-79 years). Median survival after diagnosis was 27 years, while
median age at diagnosis was 38 years. During follow-up, twenty-three patients died prior to ERT, with a median age at
death of 55 (range 23-77 years). Use of wheelchair and/or respiratory support and patients’ score on the Rotterdam
Handicap Scale (RHS) were identified as prognostic factors for survival. Five-year survival for patients without a wheelchair
or respiratory support was 95% compared to 74% in patients who were wheelchair-bound and used respiratory support.
In a Dutch subgroup of 99 patients, we compared the observed number of deaths to the expected number of deaths in
the age- and sex-matched general population. During a median follow-up of 2.3 years, the number of deaths among the
Dutch Pompe patients was higher than the expected number of deaths in the general population.
Conclusion: Our study shows for the first time that untreated adults with Pompe disease have a higher mortality
than the general population and that their levels of disability and handicap/participation are the most important
factors associated with mortality. These results may be of relevance when addressing the effect of ERT or other
potential treatment options on survival.
Keywords: Pompe disease, survival, acid maltase deficiency, lysosomal storage disease, glycogen storage disease
type II, prognostic factors, natural course, patient reported outcome measures
Background
Pompe disease, synonymously ‘acid maltase deficiency’ or
‘glycogen storage disease type II’, is a metabolic myopathy
caused by deficiency of the enzyme acid alpha-glucosidase
and resulting in intralysosomal accumulation of glycogen.
This autosomal recessive disorder is mainly characterized
by progressive loss of muscle strength and respiratory
function due to destruction of muscle tissue [1,2]. Because
of its low frequency of approximately 1 in 40,000 births
and the broad ethnic spreading [3-5], Pompe disease is a
true orphan disease with the associated problem of collect-
ing data in sufficiently large groups. Clinical heterogeneity
is an additional complicating factor [5,6]. Classic infantile
Pompe disease, the most severe form, presents in the first
months of life with generalized muscle weakness and car-
diac hypertrophy. Without treatment these infants die
* Correspondence: d.gungor@erasmusmc.nl
1Center for Lysosomal and Metabolic Diseases, Erasmus MC University
Medical Center, Dr. Molewaterplein 60, 3015 GJ Rotterdam, the Netherlands
Full list of author information is available at the end of the article
Güngör et al. Orphanet Journal of Rare Diseases 2011, 6:34
http://www.ojrd.com/content/6/1/34
© 2011 Güngör et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
before age one. Later-onset forms of Pompe disease com-
prise childhood, juvenile, and adult cases. The majority of
these patients present with symptoms in adulthood with
limb- girdle weakness and respiratory problems [5].
For a long time, supportive care such as respiratory
support was the only way of managing Pompe disease,
but in the course of 2006 enzyme replacement therapy
(ERT) with recombinant human alpha-glucosidase
became available. Clinical trials showed that ERT can
ameliorate motor outcome, improve cardiomyopathy
and prolong survival in classic infantile Pompe disease
[7-11]. In children and adults treatment with ERT has
been shown to stabilize respiratory function and to
improve muscle function [12-16].
In contrast to classic infantile Pompe disease, in which
survival is a key outcome measure to describe the nat-
ural course of the disease and to evaluate the effects of
treatment, information on mortality in adults with
Pompe disease has been lacking. The present study was
performed to fill the gap of knowledge on the impact of
Pompe disease on survival in untreated adult patients,
using data collected prospectively in an international
patient survey prior to the introduction of ERT. The
objective was to determine natural course survival in
adult patients with Pompe disease, to compare this to
the general population and to assess differences in survi-
val between subgroups of patients.
Methods
Data
Data were collected between May 2002 and December
2009 as part of an ongoing study on the natural course
of Pompe disease (’Pompe Survey’) e.g. [6,17] in which
patients complete a number of self-report questionnaires
each year, gathering information on medical history,
current disease status, use of care and quality of life.
Patients were recruited through patient organizations
affiliated with the International Pompe Association
(IPA) in Australia, Canada, Germany, the Netherlands,
the United Kingdom and the United States. Inclusion
criteria for the Pompe Survey were a diagnosis of
Pompe disease and an age above 2 years. The present
analyses only include patients of 18 years and older with
late-onset Pompe disease.
For the Dutch patients, more information was avail-
able as Erasmus MC was designated as the single refer-
ral center for treatment and longitudinal follow-up of
Pompe patients in the Netherlands.
All research protocols were approved by the medical
ethics committee of Erasmus MC and/or the Central
Committee on Research Involving Human Subjects.
Written informed consent was obtained from all
patients.
Explanation of variables
For the international participants in the Pompe Survey,
the date of the last completed questionnaire before
December 2009 was considered as the date of last fol-
low-up. For the Dutch subgroup, the date of last follow-
up was the last visit at our hospital in 2009 or the date
of the last completed questionnaire, whichever came
last.
When the date of death for the deceased was not
exactly known it was estimated to be halfway between
the date of the last completed questionnaire and the
date at which the next questionnaire should have been
completed.
The date of diagnosis was estimated as precisely as
possible according to the information provided in the
questionnaires.
To assess the level of participation (defined as a per-
son’s involvement in life situations; previously called
‘Handicap ’) [18,19], the Rotterdam Handicap Scale
(RHS) was used. The RHS consists of 9 questions on
the topics of mobility, kitchen tasks, domestic tasks, lei-
sure activities, travelling and work or study. The scores
per item range from 1 (’unable to fulfil the task or activ-
ity’) to 4 (’complete fulfilment of the task or activity’). If
an item is not applicable to a patient, a score of 0 is
given. The total score is calculated as the sum of the
scores per item * 9/(9-number of non-applicable or
missing items) [17,20]. The RHS score thus ranges from
9 to 36 and in the present analysis the number of items
necessary to calculate a score was 5 out of 9 questions.
To assess disability level at study entry patients were
divided into four groups: 1) no wheelchair or respiratory
support, 2) only wheelchair, 3) only respiratory support
and 4) both wheelchair and respiratory support. No divi-
sion was made between partial and fulltime respiratory
support, or whether it was invasive or non-invasive.
According to their nationality patients were divided
into the following groups: Netherlands, United King-
dom, United States, Germany, Canada, Australia and
other (Denmark, Austria, Switzerland, Spain, Italy, New
Zealand, Greece, Taiwan and Luxembourg).
Statistical analysis for survival from diagnosis and from
study entry
Survival was calculated from the date of diagnosis or
study entry until the date of last follow-up, start of ERT
or death. The survival times of patients who were alive
at study end or lost to follow-up were censored. The
survival times of the patients were also considered cen-
sored at the initiation of ERT.
For survival from diagnosis and from study entry, the
influence on survival was tested for the following vari-
ables: gender, age at diagnosis, and nationality. The
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variables age at entry, disability level and RHS score
were only tested for survival from study entry.
For survival from diagnosis, the PROC PHREG
method in SAS was used, because most of our patients
were enrolled months or years after diagnosis. This
means that the data are ‘left-truncated’, as opposed to
usual time-to-event data where all patients are followed
from diagnosis. Estimates of survival from diagnosis in
case not all patients enter the cohort study at the time
of diagnosis require special calculations as described by
Kurtzke [21].
Univariate analysis for survival from study entry was
estimated by using the Kaplan-Meier method. Factors
influencing survival were identified with the log-rank
test. Multivariate analysis was performed with the Cox
proportional-hazards method.
Mortality of Dutch patients compared to the general
population
Death probabilities from study entry were compared
between the Dutch Pompe patients and the general
population using death probabilities derived from the
Dutch Central Bureau of Statistics (CBS) [22]. For each
case of our study population, the death probability per
follow-up year of someone of the same age and gender
from the general population was taken for comparison.
Annual death probabilities per person were summed up
and the sum of these cumulative death probabilities of
the matched persons from the general population was
used as the expected number of deaths. This was then
compared to the observed number of deaths in our own
cohort using the Poisson distribution.
All analyses were performed using SAS (version 9.2)
or SPSS (version 15.0). Statistical significance was
defined as a p-value ≤ 0.05 for all analyses.
Results
Patient characteristics
As of December 2009, 303 adult patients were enrolled
in the Pompe Survey. Thirty-five of them were excluded
from the analyses. These were patients who had pro-
vided too little information about their diagnosis (n =
8), patients with only baseline data available (n = 15),
patients already receiving ERT at study entry (n = 2)
and patients with important data missing such as date
of birth (n = 10). Thus, the current analyses covering
the years 2002 to 2009 comprise a total of 268 adults
with Pompe disease from 15 different countries. Patient
characteristics are summarized in Table 1.
At study entry patients’ age varied between 19 and 79
years with a median age of 48 years. This did not differ
significantly between countries. The median age at diag-
nosis was 38 (range 1-68) years. Median follow-up time
from study entry was 3.5 years, with a maximum of 7
years. Seventy-eight percent of the patients were fol-
lowed for 2 years or more and 62% of the patients for 3
years or more. Differences in disability level between
countries were found, with the lowest rates of wheelchair
and ventilator use in the Dutch patient group (32% and
26%, respectively). Almost all Dutch patients carried the
most common c.-32-13T >G (IVS1) GAA mutation in
combination with a fully deleterious mutation on the
other allele. The c.-32-13T>G (IVS1) is a splice-site muta-
tion leading to 10-20% residual activity of acid alpha-
glucosidase and a broad clinical spectrum [23].
Mortality
For 34 of the 268 patients, a death confirmation was
received from the patient organization or the family.
The median age at death was 56 years and did not differ
significantly between countries. In 23 of the 34 cases
information on cause of death was not available. For the
Dutch patients (n = 9), causes of death were reported as
respiratory insufficiency (n = 3), myocardial infarction
Table 1 Patient Characteristics of 268 untreated adult
patients with Pompe disease
Female, n (%) 141 (53)
Median age at study entry, years (range) 48 (19-
79)
Median age at diagnosis, years (range) 38 (1-68)
Number of patients diagnosed in age categories of 15 years,
n (%)
<15 years 22 (8)
16-30 years 59 (22)
31-45 years 115 (43)
46-60 years 61 (23)
>61 years 11 (4)
Nationality, n (%)
Netherlands 99 (37)
Germany 48 (18)
US 69 (26)
UK 20 (8)
Australia 13 (5)
Canada 9 (3)
Other 10 (4)
Median disease duration at entry, years (range) 9 (0-32)
Median follow up time, years (range) 3.5 (0.02-
7)
Disability level at study entry, n (%)
No wheelchair use or respiratory supportª 127 (47)
Wheelchair use 34 (13)
Use of respiratory support 39 (15)
Both wheelchair use and respiratory support 68 (25)
Median RHS score* at study entry (range) (n = 258) 27 (9-36)
Continuous variables are expressed as median (range). Categorical variables
are expressed as n (%). ª’Respiratory support’ includes partial and fulltime,
invasive and non-invasive respiratory support *RHS assesses the level of
participation/handicap; score varies between 9 (severe participation
restrictions) and 36 (no participation restrictions).
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(n = 2), aortic dissection (n = 1) and breast cancer (n =
1). For two of them, cause of death was not known.
Characteristics of the deceased patients are listed in
Table 2. Data from only 23 of the deceased patients
(median age at death 55 years) could be used to esti-
mate survival prior to ERT, since the other 11 received
ERT prior to their death.
Survival from diagnosis
The estimated median survival after diagnosis -without
enzyme replacement therapy- was 27 years. The esti-
mated 5-year survival after diagnosis was 95%. At 10,
20 and 30 years this was 83, 65 and 40%, respectively
(Figure 1).
Univariate and multivariate analysis showed that none
of the tested factors were related to survival after
diagnosis.
Because the time between the start of ERT and death
was mostly less than one year and these patients were
already severely affected when they started ERT, we per-
formed a second analysis including all patients who died
within 18 months after start of ERT (n = 9). To be con-
sistent with the deceased patients, the follow-up time
for all other patients on ERT was also extended by 18
months. In this analysis with 32 events, only age at diag-
nosis, accounting for gender and nationality, was related
to survival (Hazard Ratio 1.55 per 10 years of age P <
0.01).
Survival from study entry
The Kaplan-Meier survival curve from study entry is
shown in Figure 2. After 5 years of follow-up, 88% of
the patients not yet receiving ERT were still alive.
Univariate analysis revealed a statistically significant
difference in survival between groups based on disability
level (overall p = 0.002 log-rank, Figure 3), RHS score
(overall p = 0.002 log-rank, Figure 4) and age at study
entry (overall p = 0.03 log-rank). After five years 95% of
patients without a wheelchair or respiratory support sur-
vived, while this was only 74% for patients with both
wheelchair and respiratory support at study entry. Table
3 shows the 5-year survival with respect to potential
prognostic factors. Multivariate analysis of the factors
age at study entry, gender, nationality and disability
level showed a significant effect of disability level (p =
0.01), i.e. less disability at study entry was associated
with better survival. Analyzing RHS score instead of
Table 2 Characteristics of deceased patients (34 patients
died in total, 23 of them prior to ERT)
34 (All deceased
patients)
23 (died prior
to ERT)
Female, n (%) 16 (47) 12 (52)
Median age at study entry, years
(range)
54 (20-75) 51 (20-75)
Median age at death, years
(range)
56 (23-78) 55 (23-77)
Median age at diagnosis, years
(range)
42 (13-66) 42 (13-59)
Median disease duration, years
(range)
14 (2-27) 16 (2-27)
Age at diagnosis in categories of
15 years, n (%)
0-15 years 3 (9) 3 (13)
16-30 years 6 (18) 3 (13)
31-45 years 13 (38) 10 (44)
46-60 years 10 (29) 7 (30)
>61 years 2 (6) 0
Nationality, n (%)
Netherlands 9 (27) 5 (22)
Germany 4 (12) 4 (17)
US 13 (38) 8 (35)
UK 4 (12) 3 (13)
Australia 1 (3) 0
Canada 2 (6) 2 (9)
Other 1 (3) 1 (4)
Disability level at study entry, n
(%)
No wheelchair use or
respiratory support ª
4 (12) 4 (17)
Wheelchair use 6 (18) 4 (17)
Use of respiratory support 7 (21) 4 (17)
Both wheelchair use and
respiratory support
17 (50) 11 (48)
Median RHS score* at study entry
(range)
23 (9-36) (n = 33) 22 (9-36)
Continuous variables are expressed as median (range). Categorical variables
are expressed as n (%). ª ‘Respiratory support’ includes partial and fulltime,
invasive and non-invasive respiratory support. * RHS assesses the level of
participation/handicap; score varies between 9 (severe participation
restrictions) and 36 (no participation restrictions.
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Figure 1 Survival estimates of 268 untreated adults with
Pompe disease from diagnosis until end of study, start of ERT
or death. Twenty-three patients died during follow-up.
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disability level showed that a higher RHS score at study
entry was also associated with better survival (p <
0.001). In the analysis including 32 deceased patients,
the factors age at study entry (p = 0.01) and disability
level (p = 0.002) were significantly related to survival.
When RHS score was analyzed instead of disability level
both age (p = 0.01) and RHS score (p < 0.001) were sig-
nificantly associated with survival.
Mortality of Dutch Pompe patients compared to the
general Dutch population
For this part of the analyses 99 Dutch patients, with
median age at entry 50 (range 24-79) years, were
included. The Dutch subgroup included 5 deceased
patients before start and 4 after start of ERT. The med-
ian age at death was 55 (range 41-78) years. Two of the
patients who died after start of ERT had died during the
first year of treatment; one other had died 18 months
after start of ERT and one had started and stopped ERT
in the year before death. These were all severely affected
patients using a wheelchair and/or respiratory support
before start of ERT. To compare the probability of
death in the Dutch Pompe patient group with that in
the general Dutch population two analyses were per-
formed: one taking into account only the 5 deaths
before start of ERT (median follow-up time 2.3 years)
and one taking into account 9 deaths, while in the latter
analysis extending the follow-up time after start of ERT
with 1 year for every patient on ERT (median follow-up
time 3.3 years). Table 4 shows the results.
Discussion
Using data from the Pompe Survey, a long-term, dis-
ease-specific database using patient-reported outcome
measures, we were able to perform the first study on
survival and prognostic factors in adults with Pompe
disease.
Over a prospective follow-up period of 7 years 34 of
268 patients died, 23 of them prior to ERT. Some of
these patients died relatively young (23 years) and some
reached very high ages despite Pompe disease (78 years).
By using cumulative death probabilities of persons from
the general population matched by age and gender, our
study shows for the first time that mortality in adults
with Pompe disease is higher than in the general
population.
We also found that in our group of patients, diagnosed
at a median age of 38 years, 17% died ten years after diag-
nosis. The median (50%) survival was estimated at 27
years after diagnosis. In an earlier study on the relation
between disease severity and disease duration based on
Pompe Survey data, we showed that 10-15 years after
diagnosis 50% of the patients were wheelchair-bound or
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Figure 2 Kaplan Meier survival estimates of 268 untreated
adults with Pompe disease from study entry until end of
study, start of ERT or death. Twenty-three patients died during
follow-up.
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Figure 3 Kaplan Meier survival estimates of 268 untreated
adults with Pompe disease from study entry until end of
study, start of ERT or death by disability level. Twenty-three
patients died during follow-up. ‘Respiratory support’ includes partial
and fulltime, invasive and non-invasive respiratory support. P-value
denotes result from log-rank test for trend.
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Figure 4 Kaplan Meier survival estimates of 268 untreated
adults with Pompe disease from study entry until end of
study, start of ERT or death by RHS score. (RHS score was
divided into tertiles for comparison. RHS1 = score <23, RHS2 =
score 23-30, RHS3 = score >30). Twenty-three patients died during
follow-up. P-value denotes result from log-rank test for trend.
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ventilator dependent [24]. Thus, although Pompe disease
in adults generally manifests as a slowly progressive dis-
order, it seriously affects the lives of patients.
Several factors in our study had a significant effect on
survival. For patients without a wheelchair or respiratory
support the 5-year survival from entry was 95%, while
for patients with a wheelchair and respiratory support
this was 74%. In practice this means that patients with a
wheelchair and/or respiratory support have a shorter life
expectancy at any age compared to patients without
wheelchair and respiratory support. RHS score at study
entry, indicative of the level of handicap or participation,
also was significantly associated with survival. Whether
the RHS score is also useful as a prognostic tool in clini-
cal practice is a topic for further investigation.
The strength of our study is its prospective design, the
regular follow-up, the representation across countries,
and the large sample size, especially for a rare disorder
such as Pompe disease. In orphan diseases, it is quite
unique to be able to gather information on a large
group of patients over so many years, especially prior to
therapeutic intervention. Our prospective data collection
was achieved by relying on patient reported outcome
measures through a close collaboration with patient
organizations. This approach enabled data collection
without the support of a large physician’s network that
is -in orphan diseases-usually activated only after the
introduction of a therapy. Our approach may stand
model for data collection in other rare diseases. Since
almost all newly diagnosed Pompe patients currently
start with enzyme replacement therapy, this study might
have been the very last chance to collect data on the
natural course of Pompe disease.
Nevertheless, some methodological issues need further
attention. Firstly, our patients were followed from 2002
onwards, which means that the majority entered the
study at some cross-sectional point of their illness. The
ideal method would have been to follow all patients
from the time of disease onset or diagnosis until death.
However, if we had applied those restrictions our study
population would have been too small and the follow-
up period would have been too short. Therefore, the
next best thing was to also include the patients diag-
nosed before entering the study. This led to so-called
‘left-truncated’ data, with a grey area between diagnosis
and study entry in which other patients may have died
without entering our study, and could have caused an
overestimation of the median survival. Additionally,
because all data in the Pompe Survey are provided
voluntarily, some deaths among enrolled patients who
eventually became censored due to loss-to-follow-up (n
= 37) may not have been reported.
Table 3 Summaries of 5-year survival from study entry
according to potential prognostic factors (23 deceased
patients)
Prognostic factors n 5-year survival
percentages
P-value*
Gender 0.7
Women 141 86
Men 127 91
Age at diagnosis 0.4
0-15 years 22 81
16-30 years 59 92
31-45 years 115 89
46-60 years 61 82
>61 years 11 100
Age at entry 0.03
18-30 years 32 91
31-45 years 85 94
46-60 years 104 89
>61 years 47 77
Nationality 0.7
Netherlands 99 90
Germany 48 93
US 69 85
UK 20 67
Other° 32 93
Disability level at study entry 0.002
No wheelchair use or
respiratory support ª
127 95
Wheelchair use 34 91
Use of respiratory support 39 89
Both wheelchair use and
respiratory support
68 74
RHS score at study entry* 0.002
1 85 74
2 85 95
3 88 97
* Log rank test for the Kaplan-Meier curves, overall p-values of univariate
analyses. ° Due to small groups Canada and Australia were classified into the
category “other”. ª ‘Respiratory support ‘includes partial and fulltime, invasive
and non-invasive respiratory support. *RHS score was divided into tertiles for
comparison. 1) < 23, 2) 23-30, 3)>30.
Table 4 Mortality of 99 Dutch Pompe patients compared to general Dutch population
Analysis Median follow-up time (range) Observed no. deaths (O) Expected no. deaths (E) * Ratio (O/E) P -value
1 2.3 (<1 month-7 years) 5 2.3 2.2 0.09
2 3.3 (<2 months-7 years) 9 2.8 3.2 0.002
Analysis 1: 5 deceased patients before start of ERT Analysis 2: including 4 patients who died after start of ERT with follow-up of every patient on ERT extended
with 1 year after start of ERT. * According to death probabilities derived from Dutch Central Bureau of Statistics.
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Second, differences in wheelchair and ventilator use
were observed between countries, with the Dutch
patients tending to be less severely affected on average.
This may be explained by the fact that the Dutch group
includes almost all patients known in the Netherlands,
while the inclusion through patient organizations in the
other countries may have led to a larger proportion of
more severely affected patients. This may have affected
the estimation of median survival time, but does not
influence our main conclusions that mortality in adults
with Pompe disease is higher compared to the general
population and is associated with disease severity.
Furthermore, our patients were followed for up to 7
years, but median follow-up time was 3.5 years.
Although a longer follow-up of untreated patients would
offer more insight in their survival, such a study will be
difficult to do as most patients currently receive ERT.
Because our aim was to investigate the natural course
survival, we censored patients at the initiation of ERT.
This means that 11 patients who died after start of ERT
were not included as deceased patients in our initial
analysis. Most (n = 9) of these patients died within 1.5
year after start of ERT, or stopped ERT after a few infu-
sions. As this treatment period is relatively short, we
also performed analyses including these patients.
Excluding these patients could have led to an underesti-
mation of the number of deaths as these patients were
already severely affected at the point they started ERT.
All of them were wheelchair-bound and/or used respira-
tory support and most probably would also have died
without ERT. For the same reason, in our comparison
of death probabilities between the Dutch subgroup and
the general population we also included the 4 patients
who died shortly after start of ERT.
Unfortunately, information on cause of death was
lacking for the majority of the deceased patients. How-
ever in our study, mortality was compared with the data
obtained from the Dutch Central Bureau of Statistics,
which reports deaths irrespective of the cause. This
comparison showed that the difference in mortality
between the two groups was statistically significant. This
in itself is important information, which can be used to
evaluate the severity of disease and may serve as a refer-
ence when comparing the mortality of patients under
treatment. With regard to the reported causes of death,
it seems likely that death due to respiratory insufficiency
is related to Pompe disease [25,26]. Other causes, such
as aortic dissection can also (in)directly be related to
Pompe disease, as it may be a consequence of glycogen
accumulation in vascular smooth muscle [27].
Whether timely start of ERT can increase survival of
adults with Pompe disease is currently unknown. In a
recently published randomized controlled trial of alglu-
cosidase alfa in late-onset Pompe disease, significant
differences in walking distance and pulmonary function
between the alglucosidase alfa and placebo groups were
found [16]. Considering these results, and given the fact
that most patients die of respiratory failure, it might be
expected that ERT will also positively influence life
expectancy. The present study, in which we show that
Pompe disease has a serious negative impact on the life
span of untreated adult patients, allows for future eva-
luation of the effect of ERT with respect to this impor-
tant parameter.
Conclusion
Our study shows for the first time that mortality of
untreated adults with Pompe disease is high compared
to the general population. Both the need of a wheelchair
and ventilator and a low RHS score are associated with
higher mortality. Our results can serve as reference for
future studies addressing survival of patients treated
with ERT or alternative interventions. This information
will also be valuable for families, genetic counsellors,
and other health-care professionals when Pompe disease
is diagnosed. Future studies should focus on identifying
other factors -environmental or genetic- that may deter-
mine survival or disease progression in adults with
Pompe disease, with or without treatment.
Abbrevations
CBS: Dutch Central Bureau of Statistics; ERT: enzyme
replacement therapy; GAA: the gene coding for acid
alpha-glucosidase; RHS: Rotterdam Handicap Scale.
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